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Abstract: Azilsartan, an angiotensin II type 1 (AT1) receptor blocker (ARB), was recently 
approved by regulatory authorities for treatment of hypertension and is the 8th ARB to join the 
clinical market. This article discusses the medical reasons for introducing a new AT1 receptor 
blocker and reviews the experimental and clinical studies that have compared the functional 
properties of azilsartan to those of other ARBs. The main question addressed is: Does azilsartan 
have distinguishing features that should motivate choosing it over any of the other sartans for 
use in clinical practice? Based on studies conducted to date in hypertensive patients without 
serious comorbidities, azilsartan appears to be characterized by a superior ability to control 
24-hour systolic blood pressure (BP) relative to other widely used ARBs including valsartan, 
olmesartan, and candesartan, and presumably others as well (eg, losartan). Compared to these 
other ARBs, azilsartan may increase the BP target control and response rate by an absolute value 
of 8%–10%. Greater antihypertensive effects of azilsartan might be due in part to its unusually 
potent and persistent ability to inhibit binding of angiotensin II to AT1 receptors. Preclinical 
studies have indicated that azilsartan may also have potentially beneficial effects on cellular 
mechanisms of cardiometabolic disease and insulin sensitizing activity that could involve more 
than just blockade of AT1 receptors and/or reduction in BP. However, the clinical relevance of 
these additional actions is unknown. Given that the general ability of antihypertensive drugs 
to protect against target organ damage is largely mediated by their ability to decrease BP, the 
enhanced antihypertensive effects of azilsartan should serve to justify clinical interest in this 
ARB relative to other molecules in the class that have a lower capacity to reduce BP.
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Introduction and background
Nonpeptide antagonists of the angiotensin II type 1 (AT1) receptor constitute a very 
useful and widely prescribed class of antihypertensive drugs.1 The development of 
AT1 receptor blockers (ARBs) can be traced back to the pioneering work of scientists 
at Takeda Pharmaceuticals who described a series of benzylimidazole compounds that 
inhibited the ability of angiotensin II to stimulate vascular contraction and increase blood 
pressure (BP).2,3 Using a modeling strategy based on the original Takeda compounds, 
scientists at DuPont derived losartan, the first ARB introduced for the clinical treatment of 
hypertension.4 After the Food and Drug Administration (FDA) approved losartan in 1995, 
a host of other AT1 receptor antagonists were rapidly introduced and a total of six ARBs 
were already clinically available by the time olmesartan   medoxomil joined the market 
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in 2002. More than 15 years after the clinical introduction of 
losartan, the FDA approved Takeda’s azilsartan medoxomil 
as the 8th ARB for the treatment of hypertension.5 Azilsartan 
medoxomil has also been approved in Europe for treatment of 
hypertension and the parent compound, azilsartan, has recently 
been approved in Japan.6,7
The purpose of this paper is to address two related 
  questions: (1) Why develop another AT1 receptor antagonist 
for clinical practice when over a half dozen ARBs are already 
clinically available? (2) Is there anything special about the 
most recently approved ARB azilsartan compared to the old 
“standbys” that have been in clinical use for many years?
Principal reasons for developing 
another ARB
To achieve better control of BP  
than that provided by other ARBs
Much has been written about the putative benefits of ARBs 
mediated by mechanisms said to be independent of reductions 
in BP. However, the ability of ARBs to protect against target 
organ damage and improve clinical outcomes is still consid-
ered to be largely mediated by their ability to decrease BP.8,9 
Because it is the decrease in BP that is believed to be mainly 
responsible for the clinical cardiovascular (CV) benefits of all 
types of antihypertensive drugs, the FDA recently permitted 
pharmaceutical companies to make the “general, qualitative 
claim of cardiovascular outcome benefits” for approved anti-
hypertensive drugs without requiring companies to submit 
clinical cardiovascular outcome data for such drugs.10 This 
appears to be the first time that the FDA has consented to 
“extending an outcome claim across a set of pharmacologi-
cally distinct drug classes.” In essence, the FDA has accepted 
BP-lowering that meets regulatory standards as a surrogate 
for reduction in fatal and nonfatal cardiovascular events, 
primarily strokes and myocardial infarctions.10 Although the 
FDA’s position is not directly relevant for regulatory pur-
poses outside of the USA, it is scientifically consistent with 
the position statements of major hypertension authorities in 
other parts of the world. For example, experts representing 
the European Society of Hypertension have also concluded 
that “the main benefits of antihypertensive treatment are due 
to lowering of BP per se, and are largely independent of the 
drugs employed.”11
Despite the fact that all approved AT1 receptor blockers 
can lower BP, many patients treated with currently available 
ARBs do not achieve BP treatment goals.12–14 This is often 
due to the fact that hypertension is mediated by factors other 
than just increased activity of the renin angiotensin system. 
In some cases, however, it is also possible that patients are not 
achieving sufficient blockade of the renin-angiotensin system 
due to issues related to ARB pharmacodynamics, pharma-
cokinetics, and or adherence to therapy. Although treatment 
of hypertension with multiple drugs is helpful for controlling 
BP in patients in whom hypertension is determined by more 
than just the renin-angiotensin system, the availability of an 
ARB with greater ability to lower BP than older ARBs could 
nevertheless be of clinical value. Thus, one could medi-
cally appreciate the introduction of still another ARB if the 
molecule was able to safely provide better BP control and 
presumably therefore, better cardiovascular protection than 
that afforded by maximum approved doses of existing ARBs. 
Of course, this assumes that the particular structure of the 
sartan does not confer adverse effects that could undermine 
the cardiovascular benefits otherwise expected from its ability 
to block AT1 receptors and reduce BP.
Do any of the old clinical ARBs stand out with respect 
to the ability to lower BP? The standard ARBs that have 
been clinically available for many years have long been 
recognized to show differences among each other with 
respect to factors such as plasma half-life, potency for AT1 
receptor blockade, and slope of the dose response curve for 
lowering BP.15–17 However, in studies including endpoints 
reached after chronic titration to maximum approved doses 
of various sartans, it has been difficult to show that any one 
ARB in particular stands out with respect to the ability to 
lower BP.18 Head-to-head studies performed with lower drug 
doses beg the question as to whether any of the differences 
in BP-lowering capacity observed among various ARBs 
might simply be overcome by conventional dose adjustments 
that achieve maximum BP responses. Among some ARBs, 
differences in BP-lowering ability caused by differences in 
half-life and or potency for AT1 receptor blockade might be 
eliminated just by insuring that the maximum approved doses 
are consistently administered on a daily basis.
There have been several reports of head-to-head trials 
indicating that the maximum approved dose of losartan is less 
effective than the maximum approved doses of other ARBs 
in controlling BP through some or all portions of the 24-hour 
dosing interval.19–22 Even at high doses, losartan appears less 
effective in lowering BP than most other ARBs owing to its 
relatively flat dose response curve.23 Post hoc studies based 
on either meta-analysis of different trials lumped together, 
or on review of BP data from patient medical records have 
also indicated that losartan may be less effective than some 
other ARBs in reducing BP when used as monotherapy or for 
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combination therapy.13,14,24 Given the paucity of head-to-head 
controlled clinical trials, there has been little or no definitive 
evidence that any ARB provides better BP control than that 
provided by maximum approved doses of competitors other 
than losartan. However, as discussed further below, recent 
head-to-head studies comparing azilsartan to other ARBs 
have changed this situation.25–28
To provide significant clinical value 
beyond that afforded by good BP control
Notwithstanding the consensus view that the CV outcome 
benefits of all antihypertensive drugs can be largely attributed 
to BP-lowering, it is possible that new antihypertensive drugs 
might be introduced with “other properties” in addition to 
BP-lowering that could contribute to differences in CV events 
and or differences in effects on other significant clinical 
endpoints. In fact, the FDA has stated that “individual drugs, 
and perhaps drug classes, may have differences in effects on 
other important endpoints, presumably because of pharma-
cological effects other than BP reduction.”10   According to 
the FDA, “these other properties of antihypertensive drugs 
(eg, effects on heart failure or diabetic nephropathy) often 
will be a reasonable basis for deciding which drugs to use 
or which drugs to use first.”10
It is well known that many factors besides BP can 
influence CV outcomes and that many patients suffer from 
cardiovascular events despite having their hypertension under 
good control with a drug that inhibits the renin angiotensin 
system. Clearly, multiple risk factor intervention is required 
for purposes of target organ protection and should be 
encouraged as much as possible.29 Nevertheless, one could 
appreciate the introduction of another ARB if the molecule 
could do more than lower BP and safely provide a significant 
degree of added CV protection beyond that achieved by 
lowering BP with typical ARBs. Unfortunately, for ARBs in 
general, the added cardiovascular benefits mediated through 
mechanisms beyond BP-lowering appear modest at best and 
remain open to question.8,29–32
It is generally accepted that AT1 receptor blockers can 
help protect against the progression of diabetic nephropathy 
and that some of this benefit may involve more than BP-
lowering.33 In addition, some ARBs may be more effective 
than others in reducing proteinuria in patients with diabetic 
nephropathy despite providing similar reductions in BP.34 
Nevertheless, the main renoprotective actions of ARBs 
in general are largely mediated by their effects on BP.9 
Interestingly, the FDA has not extended a general claim of 
nephroprotective benefits to all molecules in the ARB class 
despite the fact that all approved ARBs inhibit AT1 signaling 
and lower BP. However, clinical practice guidelines from 
major medical societies treat the renal protective actions of 
ARBs as a class effect and recommend ARBs among the 
first line drugs for treatment of hypertension in diabetics. 
In any case, one might be motivated to select a new ARB 
for clinical use over existing ARBs if it could be shown to 
safely provide better renoprotection either through better BP 
control, more effective AT1 receptor blockade, or any other 
beneficial mechanism.
Enhanced protection from developing diabetes is another 
example of an added clinical benefit that might help motivate 
the selection of a newer ARB over existing ARBs. Although 
multiple risk factor intervention including nonpharmacologic 
and pharmacologic strategies can be useful for reducing the 
risk for diabetes as well as for cardiovascular disease,29,31,35,36 
the presence of an extra antidiabetic effect in a reasonably 
priced and safe antihypertensive drug could still represent a 
useful clinical bonus. This is true regardless of whether or 
not prevention of new onset diabetes reduces cardiovascular 
risk, or any other physical problems, because the diagnosis 
itself carries psychological and practical burdens.
While it is generally believed that angiotensin recep-
tor blockers can reduce the risk for new onset diabetes, 
the absolute antidiabetic effects reported so far have been 
rather weak.29,31,32,37 The best randomized, double blind trial 
on the antidiabetic effect of an AT1 receptor blocker was 
performed with valsartan.32 In patients with impaired glucose 
metabolism, valsartan afforded a relative risk reduction for 
incident diabetes of 12.4% after adjusting for differences 
from the control group for presence of metabolic syndrome 
at baseline and frequency in use of other antihypertensive 
drugs. However, the absolute risk reduction for incident 
diabetes with valsartan was only 3.7% and many patients 
taking valsartan still developed diabetes. Thus, there is clear 
room for improvement in the putative antidiabetic effects of 
AT1 receptor blockers.31
Is there anything special about 
azilsartan?
Discovery path and chemical structure
Azilsartan was discovered through the efforts of Takeda sci-
entists to find a new class of AT1 antagonists by modifying the 
tetrazole ring present in candesartan.38,39 The tetrazole ring is 
also present in many other clinically approved ARBs includ-
ing irbesartan, olmesartan, losartan, and valsartan. As shown 
in Figure 1, the chemical structure of azilsartan is very similar 
to the structure of candesartan and differs only by replacement 
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of candesartan’s 5 member tetrazole ring with the 5 member 
oxo-oxadiazole ring of azilsartan. This chemical modifica-
tion served to make azilsartan less acidic and more lipophilic 
than candesartan. The oxo-oxadiazole ring in azilsartan is not 
found in any other clinically approved ARB.
Unlike candesartan, which must be orally administered 
as the prodrug candesartan cilexetil to insure adequate 
bioavailability, azilsartan has been shown to be effective 
in reducing BP when orally administered as either the ester 
prodrug, azilsartan medoxomil (TAK-491), or as the pri-
mary compound.28,38,40,41 During gastrointestinal absorption, 
azilsartan medoxomil is rapidly hydrolyzed to azilsartan 
(TAK-536), the bioactive molecule that selectively and com-
petitively blocks angiotensin II-induced activation of AT1 
receptors in an insurmountable fashion.5,38,42,43 The prodrug 
azilsartan medoxomil has never been detected in plasma after 
oral administration to humans. Azilsartan is metabolized to 
major (M-II) and minor (M-I) metabolites that do not sig-
nificantly contribute to AT1 receptor blockade.5,25
Azilsartan medoxomil has been approved in both the 
United States and Europe for treatment of hypertension.5,6 In 
2012, the parent compound azilsartan was approved in Japan 
for treatment of hypertension.7 There is nothing particularly 
remarkable about the pharmacokinetic features or safety 
profiles of azilsartan or azilsartan medoxomil versus other 
ARBs. Azilsartan is a well-tolerated molecule with a half-life 
of approximately 11 hours, is metabolized in the liver mainly 
via cytochrome P450 2C9 (CYP2C9), and is eliminated in 
both urine and feces.5,41 No unusual drug interactions have 
been observed with azilsartan or azilsartan medoxomil, and 
dosage adjustment is not required in patients with mild to 
severe renal disease or in patients with mild to moderate 
hepatic impairment.5,41
Greater antihypertensive effects  
of azilsartan than other ARBs
Azilsartan, in clinically approved doses as azilsartan 
  medoxomil, has been shown to lower 24-hour BP in 
hypertensive patients significantly more than the maximum 
approved dose of olmesartan medoxomil, the latter being 
considered by some to be one of the most potent ARBs for 
lowering BP.23,25,26 Azilsartan medoxomil has also been 
shown to lower 24-hour BP significantly more than the 
maximum approved dose of valsartan, the most widely 
prescribed drug in the ARB class.25,27,44 Specifically, in 
head-to-head studies using ambulatory BP monitoring 
in hypertensive patients without serious comorbidities, 
treatment for 6 weeks with 80 mg azilsartan medoxomil 
lowered 24-hour systolic BP by 2–4 mmHg (P , 0.01 to 
P , 0.001) more than 40 mg olmesartan medoxomil or 
320 mg valsartan, respectively (Figure 2).25,26 Azilsartan 
medoxomil also lowered 24-hour diastolic BP more than 
olmesartan medoxomil and valsartan, and was just as well 
tolerated and as safe as the comparator agents.
In a longer study comparing azilsartan medoxomil to 
valsartan, treatment with either 40 mg or 80 mg azilsartan 
medoxomil for 24 weeks reduced 24-hour systolic BP and 
clinic systolic BP significantly more than 320 mg valsartan 
(∼4 mmHg).27 Based on the results of both epidemiologic 
studies and intervention trials, various authorities have 
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Figure 1 Chemical structure of azilsartan compared to candesartan. The structures of azilsartan and candesartan are identical except that azilsartan has a 5-oxo-1,2, 
4-oxadiazole ring in place of the tetrazole ring found in candesartan and in many other ARBs including valsartan, olmesartan, losartan, and irbesartan. The 5-oxo-1,2, 
4-oxadiazole ring in azilsartan and the tetrazole ring in candesartan are highlighted in the dashed circles.
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indicated that this magnitude of additional BP-lowering may 
contribute to further reduction in cardiovascular risk.45,46
In the head-to-head studies comparing BP effects of 
different ARBs in patients with stages 1 and 2 hypertension 
and without serious comorbidities, White et al noted that 
more subjects achieved a clinic SBP goal of ,140 mmHg 
and or a .20 mmHg reduction in SBP from baseline during 
treatment with azilsartan medoxomil (58% of patients) than 
with maximum approved doses of olmesartan or valsartan 
(49% of patients, P , 0.05).25 Greater BP-lowering effects 
with azilsartan versus olmesartan or valsartan were observed 
in a variety of patient groups including those either ,65 
or .65 years of age, in black subjects or white subjects, males 
or females, and in obese and nonobese subjects.
Given the close structural relationship between azilsartan 
and candesartan, head-to-head studies comparing the BP 
effects of these two drugs are of particular interest. Recently, 
Rakugi et al reported that in a 16 week, randomized, double 
blind study of 622 Japanese patients with grade I–II essential 
hypertension, azilsartan, 20–40 mg per day by forced titra-
tion, lowered clinic systolic and diastolic BPs significantly 
more than candesartan cilexetil, 8–12 mg per day by forced 
titration (Figure 3).28 Ambulatory BP monitoring at week 
14 confirmed superior antihypertensive effects of azilsartan 
versus candesartan cilexetil over the 24-hour period, and 
during the daytime, night-time, and early morning. It should 
be noted that patients with cardiovascular disease or signifi-
cant renal or hepatic disease were excluded from this trial. 
However, approximately 20% of the subjects had diabetes, 
and greater BP effects of azilsartan versus candesartan 
cilexetil were observed in both the diabetic patients and 
the nondiabetic patients. Results for safety and tolerability 
were similar in patients treated with azilsartan versus those 
treated with candesartan cilexetil. In Japan, 40 mg/day is the 
maximum approved dose for azilsartan and 12 mg/day is the 
maximum approved dose for candesartan cilexetil.7,28
The clinical BP trials of azilsartan or azilsartan medox-
omil published to date have been mainly conducted in patients 
without serious comorbidities, although 20% of the subjects 
in the study by Rakugi et al were diabetic.28 It remains to 
be determined whether azilsartan will also provide superior 
BP-lowering action, or any type of advantage over other 
ARBs in the treatment of hypertensive patients with serious 
comorbidities such as cardiovascular disease or severe renal 
insufficiency. Although head-to-head comparisons of the 
BP-lowering actions of different ARBs in high risk patients 
are certainly feasible, it is unlikely that large scale trials will 
ever be performed to compare the effects of different ARBs 
on clinical outcomes such as myocardial infarction, renal 
failure, stroke, etc.
No head-to-head BP studies have been published that 
tested azilsartan in combination with a diuretic or calcium 
blocker versus other ARBs in combination with exactly the 
same comparator diuretic or calcium blocker. Azilsartan 
medoxomil is the only ARB that has been approved for use 
in a fixed dose combination with the diuretic chlorthalidone 
16
14 −14.3
−11.7
−10.0
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10
8
6
4
2
0
n = 229 n = 254n  = 234
P < 0.01 P < 0.001
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Figure 2 Mean changes in 24-hour systolic BP from baseline (difference from placebo) in patients with stages 1 and 2 hypertension without serious comorbidities treated 
for 6 weeks with maximum approved doses of azilsartan medoxomil (80 mg/day), olmesartan medoxomil (40 mg/day), or valsartan (320 mg/day) as reported by White et al.25 
Error bars denote limits of the 95% confidence intervals for the means.
Abbreviation: BP, blood pressure.
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whereas other ARBs are sold in fixed dose combinations with 
hydrochlorothiazide. This is noteworthy because of evidence 
indicating that typically used doses of chlorthalidone are more 
effective in lowering BP and may afford greater CV protec-
tion than typically used doses of hydrochlorothiazide.47,48 In 
a head-to-head, randomized trial, the combination of 40 mg 
azilsartan medoxomil plus 25 mg chlorthalidone was found 
to lower BP significantly more than the combination of 40 mg 
olmesartan medoxomil plus 25 mg hydrochlorothiazide.49
Greater potency of azilsartan for 
AT1 receptor blockade and potential 
relevance to its superior BP-lowering 
properties
Similar to other ARBs, azilsartan is highly selective for AT1 
receptors and has more than a 10,000-fold greater affinity for 
AT1 versus AT2 receptors.50 Like many other ARBs, azilsartan 
not only functions as a selective and competitive antagonist 
that blocks angiotensin II stimulation of AT1 receptors in an 
insurmountable fashion, it can also act as an inverse agonist 
and inhibit AT1 receptor signaling that may occur in the 
absence of angiotensin II.42 Although other ARBs can also 
potently and selectively interfere with angiotensin II induced 
activation of AT1 receptors in an insurmountable fashion, azil-
sartan appears to be characterized by a greater potency and an 
unusual capacity to persistently block AT1 receptors for longer 
periods of time than most, if not all, competitor ARBs.42,43
Table 1 shows the concentrations (IC50 values) of different 
ARBs required to inhibit binding by 50% of   radioactively 
n = 311
P < 0.0001
P = 0.0003
Azilsartan
Change in
clinic BP
from
baseline
(mmHg)
Azilsartan Candesartan Candesartan
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Figure 3 Changes in clinic systolic and diastolic BPs from baseline in Japanese patients with grade i–ii essential hypertension after treatment for 16 weeks with azilsartan or 
candesartan cilexetil as reported by Rakugi et al.28 Patients received either azilsartan, 20 mg/day for 8 weeks followed by 40 mg/day for an additional 8 weeks, or candesartan 
cilexetil, 8 mg/day for 8 weeks followed by 12 mg/day for an additional 8 weeks. In Japan, the maximum approved dose of azilsartan is 40 mg/day and the maximum approved 
dose of candesartan cilexetil is 12 mg/day. Approximately 20% of study patients had diabetes. Patients with known cardiovascular disease or significant hepatic or renal disease 
were excluded from the study.
Abbreviation: BP, blood pressure.
Table 1 Concentrations of ARBs that inhibit binding by 50% of 
radioactively labeled angiotensin ii to cell membrane preparations 
containing human AT1 receptors (iC50 values)
IC50 (nM)
No drug washout After drug washout
Azilsartan 2.6 7.4
Olmesartan 6.7 242.5
Telmisartan 5.1 191.6
irbesartan 15.8 .10,000
Valsartan 44.9 .10,000
Notes: iC50 values obtained from the study of Ojima et al. in which angiotensin ii 
radioligand binding to human AT1 receptors was tested in the presence of indicated 
drugs (no drug washout) and following a 5-hour period after drug washout.42
Abbreviations: ARB, angiotensin ii type 1 receptor blocker; iC50, half maximal 
inhibitory concentration.
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labeled angiotensin II to cell membrane preparations contain-
ing human AT1 receptors. Under the experimental conditions 
described by Ojima et al, azilsartan was found to be approxi-
mately twice as potent as either olmesartan or telmisartan, 
both of which are considered to be among the most potent 
of all clinically approved ARBs for blocking angiotensin II 
binding to AT1 receptors.42 In addition, azilsartan was found 
to be about 5 to 20 times more potent than irbesartan and 
valsartan, respectively. The greater potency of azilsartan for 
AT1 receptor blockade could help explain why azilsartan low-
ers BP more than maximum approved doses of other ARBs 
such as olmesartan and valsartan.
It should be noted that the peak plasma concentra-
tion of azilsartan achieved after oral administration of the 
80 mg maximum approved dose of azilsartan medoxomil 
is ∼10 micromolar.51 This is 5 times greater than the peak 
plasma concentration of olmesartan that is achieved after 
administration of the 40 mg maximum approved dose of 
olmesartan medoxomil (∼2 micromolar).52 This could help 
further explain the superior BP-lowering action of azilsartan 
versus olmesartan.
There are no published studies directly comparing the 
ability of azilsartan versus candesartan to inhibit bind-
ing of angiotensin II to human AT1 receptors in vitro. 
  Candesartan is considered to have a very high potency for 
binding to human AT1 receptors relative to other ARBs 
and is known to be useful in controlling hypertension in 
both diabetic and nondiabetic patients.53,54 Some studies 
have indicated that the potency of candesartan is rela-
tively similar to that of azilsartan for inhibiting binding of 
  angiotensin II to bovine adrenal cortical membranes, block-
ing   angiotensin II induced contraction of rabbit aorta, and 
acutely inhibiting pressor responses to intravenously infused 
angiotensin II.38,55   However, it should be noted that usual 
oral doses of azilsartan or azilsartan medoxomil yield peak 
concentrations of azilsartan in plasma that are 10 to 20 times 
greater than the concentrations of candesartan that are 
achieved with usual oral doses of candesartan cilexetil.51,56 
This may help explain the results of recent studies from 
Japan where the maximum approved dose of azilsartan was 
found to lower BP significantly more than the maximum 
approved dose of candesartan cilexetil.28
Very tight binding of azilsartan  
to AT1 receptors
One of the most unusual features of azilsartan reported to date 
is its ability to remain tightly bound to AT1 receptors for very 
long periods of time after drug washout. In   studies of   receptor 
binding of radioactively labeled angiotensin II conducted 
5 hours after drug washout, azilsartan showed a superpo-
tent ability to inhibit binding of angiotensin II to human 
AT1 receptors (IC50 values being more than 30–1000 fold 
lower for azilsartan than other ARBs including olmesartan, 
telmisartan, irbesartan, and valsartan, Table 1).42 Thus, in 
contrast to studies conducted without drug washout in which 
azilsartan appeared about 2–20 fold more potent than these 
other ARBs for blocking angiotensin II binding to human 
AT1 receptors, the studies conducted after drug washout 
showed azilsartan to be 30–1000 times more potent than the 
competitor ARBs.42
Time course studies of the ability of different ARBs to 
persistently block angiotensin II binding to AT1 receptors 
after drug washout have also indicated that azilsartan dis-
sociates from AT1 receptors more slowly than other ARBs 
including olmesartan, telmisartan, and valsartan (Figure 4).42 
These findings are consistent with separate studies conducted 
before and after drug washout indicating that azilsartan is 
more effective than other ARBs such as olmesartan or valsar-
tan in persistently inhibiting angiotensin II-induced increases 
in BP,43 contraction of aortic vascular strips,42 cellular accu-
mulation of inositol 1-phosphate,42 or activation of mitogen 
activated protein kinase (MAPK) in smooth muscle.57
There are no published time course studies that directly 
compare the ability of azilsartan versus candesartan to persis-
tently inhibit in vitro binding of angiotensin II to AT1 recep-
tors after drug washout. In humans, however, time course 
studies of the ability of different ARBs to inhibit pressor 
responses to intravenous angiotensin II have suggested that 
azilsartan may have slower dissociation kinetics from AT1 
receptors than candesartan.55 In addition, in normotensive 
rats studied 24-hours after an oral dose of 1 mg/kg, azilsar-
tan appeared to inhibit the pressor response to intravenous 
angiotensin II considerably more than candesartan cilexetil 
(almost 100% inhibition versus 65% inhibition for azilsartan 
versus candesartan cilexetil, respectively).38 In spontaneously 
hypertensive rats (SHR) studied up to 24 hours after oral 
dosing, azilsartan also seemed to show a greater ability to 
maintain larger reductions in BP than candesartan cilexetil 
for a sustained period of time (ie, after plasma concentrations 
had presumably begun to wane).38 Taken together, these 
studies are consistent with the possibility, but do not prove, 
that azilsartan might bind to AT1 receptors more tightly than 
candesartan.
Is very “tight” binding of azilsartan to AT1 receptors 
clinically relevant? In patients who do not take their anti-
hypertensive medications as prescribed and miss scheduled 
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drug doses, it is theoretically conceivable that azilsartan’s 
ability to tightly bind AT1 receptors for extended periods of 
time might afford a further degree of BP protection relative 
to other ARBs. Studies in animal models given a single 
dose of azilsartan have shown substantial reductions in BP 
that persist even when plasma drug levels are very low at 
24 hours after dosing.38,43 In addition, in conscious dogs with 
renal hypertension studied for 24 hours after one time oral 
dosing, the greater BP-lowering effect of 1 mg/kg azilsartan 
medoxomil versus 3 mg/kg olmesartan medoxomil appeared 
to become more prominent over time.43 It should be noted 
that the plasma half-life of azilsartan is similar to, or even 
somewhat shorter than that of olmesartan. Thus, the studies 
showing relatively prolonged functional effects of azilsartan 
compared to other ARBs cannot be readily explained by 
simple pharmacokinetic differences between the drugs.
Although the relatively unusual ability of azilsartan to 
tightly bind AT1 receptors could conceivably offer cardio-
protective advantages over other ARBs in patients who do 
not take their medications on a consistent basis, the potential 
clinical relevance of prolonged AT1 receptor binding in 
patients who carefully take their medications as prescribed 
is less clear.58 To the extent that patients faithfully take their 
medications and chronically maintain expected steady state 
drug levels, the rate at which different ARBs dissociate from 
AT1 receptors should have relatively little effect on their 
  ability to control BP over 24 hours. In patients who chroni-
cally take maximum approved doses of ARBs, there is little 
or no evidence that azilsartan’s superior ability to lower 
BP versus other ARBs is any more pronounced at 24 hours 
after dosing than it is at 1 hour after dosing. In most of the 
head-to-head clinical trials that have compared chronic 
therapy with azilsartan versus other ARBs, the superior 
antihypertensive effect of azilsartan appeared to be fairly 
consistent across the entire 24-hour dosing interval.25 Interest-
ingly, however, in Japanese patients studied by ambulatory 
BP monitoring after treatment with azilsartan or candesartan 
cilexetil for 14 weeks, the trough to peak ratios for systolic 
and diastolic BP appeared greater in the azilsartan group (0.97 
and 0.95 for systolic BP and diastolic BP, respectively) than 
in the candesartan cilexetil group (0.82 and 0.75 for systolic 
BP and diastolic BP, respectively).28 This raises the possibil-
ity that in some circumstances or patient groups, the superior 
BP-lowering effects of azilsartan over candesartan cilexetil 
or other ARBs might become more pronounced towards the 
end of the 24-hour dosing interval.
Additional effects beyond AT1 receptor 
blockade and BP-lowering
While azilsartan might be the most potent AT1 receptor 
blocker available and may reduce 24-hour BP significantly 
more than maximum approved doses of other ARBs such 
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as olmesartan, valsartan, and candesartan, it remains to be 
determined whether azilsartan will offer further clinical ben-
efits beyond those afforded by its robust ability to inhibit the 
renin angiotensin system and lower BP. Recent preclinical 
studies have indicated that azilsartan may have beneficial 
effects on cellular mechanisms of cardiometabolic disease 
through actions that could involve more than just blockade of 
AT1 receptors and/or reduction in BP.57 For example, Kajiya 
et al have reported that azilsartan is a pleiotropic ARB with 
antiproliferative effects in cultured vascular cells that may 
not strictly depend on AT1 receptor blockade.57 In addition, in 
studies in 3T3L1 cells, azilsartan has been found to promote 
adipocyte differentiation and stimulate expression of genes 
encoding peroxisome proliferator activated receptors, leptin, 
adipsin, and adiponectin more than valsartan.57 Studies in 
animal models have also shown that azilsartan or azilsartan 
medoxomil in doses similar to those used in humans can 
improve insulin sensitivity much more than larger doses of 
other ARBs such as olmesartan medoxomil or candesartan 
cilexetil.43,59 These observations could serve to motivate 
clinical studies comparing the metabolic benefits of azilsartan 
versus other ARBs in use today. Finally, in studies in a rat 
model of type 2 diabetes, azilsartan medoxomil appeared 
to be more potent than olmesartan medoxomil in reducing 
proteinuria.43 However, it remains to be determined whether 
any greater antiproteinuric effects of azilsartan are related to 
its superior ability to block AT1 receptors and reduce BP or 
to some other special property of the drug.
Summary
Based on studies conducted to date, azilsartan appears to: 
(1) be more potent than most if not all other clinically avail-
able ARBs for inhibiting binding of angiotensin II to human 
AT1 receptor membrane preparations; (2) dissociate from 
AT1 receptors much more slowly than other ARBs; and (3) 
reduce 24-hour BP in hypertensive humans without serious 
comorbidities more effectively than maximum approved 
doses of the well-known ARBs olmesartan, valsartan, and 
candesartan, each of which is considered to be more effective 
in lowering BP than losartan. However, the antihypertensive 
effects of azilsartan in hypertensive patients with serious 
comorbidities remain to be determined. Preclinical studies 
have indicated that azilsartan improves insulin sensitivity 
more than candesartan and olmesartan, and may have pleio-
tropic effects beyond AT1 receptor blockade of potential 
metabolic and cardiovascular significance. However, clini-
cal trials will be required to determine whether azilsartan 
offers further benefits beyond BP-lowering. As noted by 
many scientific authorities and as stated by the FDA, “it 
is the decrease in BP, rather than any other property of 
(antihypertensive) drugs, that is largely responsible” for their 
cardiovascular clinical benefits. Because the relationship 
between cardiovascular risk and BP is monotonic with abso-
lute risk decreasing progressively as BP decreases towards 
recommended goals, the greater antihypertensive effects of 
azilsartan serve to justify clinical interest in this recently 
approved ARB relative to other molecules in the class with 
a lower capacity to reduce BP.
Disclosures
TWK has received grant funding from the National   Institutes 
of Health and lecture honoraria from GlaxoSmithKline, 
Boehringer–Ingelheim, Takeda Pharmaceuticals North 
America, Shionogi, Pfizer, and Merck and has served as 
a consultant for Theravance Inc, Takeda Pharmaceuticals 
North America, and Daiichi Sankyo Pharmaceuticals, and 
holds stock ownership interest in GlaxoSmithKline, Bethesda 
Pharmaceuticals, Ligand Pharmaceuticals, Novartis, and 
Pfizer. TK has no potential conflicts of interest to declare.
References
  1.  Ram CV. Angiotensin receptor blockers: current status and future 
prospects. Am J Med. 2008;121(8):656–663.
  2.  Furukawa Y, Kishimoto S, Nishikawa K, inventors; Takeda Chemical 
Industries, Ltd, Osaka, Japan, assignee. Hypotensive imidazole-5-acetic 
acid derivatives. US Patent 4,355,040. October 20, 1982.
  3.  Furukawa Y, Kishimoto S, Nishikawa K, inventors; Takeda Chemical   
Industries, Ltd., Osaka, Japan, assignee. Hypotensive imidazole   
derivatives. US Patent 4,340,598, July 20, 1982.
  4.  Duncia JV , Chiu AT, Carini DJ, et al. The discovery of potent non-
peptide angiotensin II receptor antagonists: a new class of potent 
antihypertensives. J Med Chem. 1990;33(5):1312–1329.
  5.  Takeda Pharmaceuticals North America. Edarbi prescribing informa-
tion. 2011.
  6.  Takeda Pharmaceuticals Press Release. Takeda’s Edarbi® (azilsartan 
medoxomil) receives European marketing authorisation for the treat-
ment of essential hypertension. Available from: http://www.takeda.
com/press/article_43967.html. Accessed January 27, 2012.
  7.  Takeda Pharmaceuticals Press Release. New drug application approval for 
AZILVA® in Japan, a treatment of hypertension. Available from: http://
www.takeda.com/press/article_44965.html. Accessed January 26, 2012.
  8.  Staessen JA, Richart T, Wang Z, Thijs L. Implications of recently 
published trials of blood pressure-lowering drugs in hypertensive or 
high-risk patients. Hypertension. 2010;55(4):819–831.
  9.  Griffin KA, Bidani AK. Progression of renal disease: renoprotective   
specificity of renin-angiotensin system blockade. Clin J Am Soc   
Nephrol. 2006;1(5):1054–1065.
  10.  Food and Drug Administration, Center for Drug Evaluation and 
Research. Guidance for industry. Hypertension indication: drug label-
ing for cardiovascular outcome claims. United States Department of 
Health and Human Services. 2011. Available from: http://www.fda.
gov/downloads/drugs/GuidanceComplianceRegulatoryInformation/
Guidances/ucm075072.pdf
 11.  Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guide-
lines on hypertension management: a European Society of Hypertension 
Task Force document. J Hypertens. 2009;27(11):2121–2158.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
141
Azilsartan versus other ARBsVascular Health and Risk Management 2012:8
  12.  Oparil S, Silfani TN, Walker JF. Role of angiotensin receptor block-
ers as monotherapy in reaching blood pressure goals. Am J Hypertens. 
2005;18(2 Pt 1):287–294.
  13.  Ram CV , Ramaswamy K, Qian C, et al. Blood pressure outcomes in 
patients receiving angiotensin II receptor blockers in primary care:   
a comparative effectiveness analysis from electronic medical record 
data. J Clin Hypertens (Greenwich). 2011;13(11):801–812.
  14.  Petrella R, Michailidis P. Retrospective analysis of real-world 
efficacy of angiotensin receptor blockers versus other classes of 
antihypertensive agents in blood pressure management. Clin Ther. 
2011;33(9):1190–1203.
  15.  Unger T. Significance of angiotensin type 1 receptor blockade: 
why are angiotensin II receptor blockers different? Am J Cardiol. 
1999;84(10 A):9S–15S.
  16.  Song JC, White CM. Pharmacologic, pharmacokinetic, and therapeutic 
differences among angiotensin II receptor antagonists. Pharmacotherapy.   
2000;20(2):130–139.
  17.  Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 
2001;103(6):904–912.
  18.  Giles TD, Oparil S, Silfani TN, Wang A, Walker JF. Comparison of 
increasing doses of olmesartan medoxomil, losartan potassium, and 
valsartan in patients with essential hypertension. J Clin Hypertens 
(Greenwich). 2007;9(3):187–195.
  19.  Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative 
efficacy of two angiotensin II receptor antagonists, irbesartan and losartan 
in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. 
Am J Hypertens. 1998;11(4 Pt 1):445–453.
  20.  Oparil S, Guthrie R, Lewin AJ, et al. An elective-titration study of 
the comparative effectiveness of two angiotensin II-receptor blockers, 
irbesartan and losartan. Irbesartan/Losartan Study Investigators. Clin 
Ther. 1998;20(3):398–409.
  21.  Smith DH, Cramer MJ, Neutel JM, Hettiarachchi R, Koval S.   Comparison 
of telmisartan versus losartan: meta-analysis of titration-to-response   
studies. Blood Press Monit. 2003;8(3):111–117.
  22.  Weir MR, Punzi HA, Flack JM, et al. A randomized, double-blind, 
forced-titration study to compare olmesartan medoxomil versus losartan 
potassium in patients with stage 1 and 2 hypertension. Postgrad Med. 
2011;123(1):80–87.
  23.  Zannad F, Fay R. Blood pressure-lowering efficacy of olmesartan relative 
to other angiotensin II receptor antagonists: an overview of randomized 
controlled studies. Fundam Clin Pharmacol. 2007;21(2):181–190.
  24.  Nixon RM, Muller E, Lowy A, Falvey H. Valsartan vs other angiotensin II   
receptor blockers in the treatment of hypertension: a meta-analytical 
approach. Int J Clin Pract. 2009;63(5):766–775.
  25.  White WB, Weber MA, Sica D, et al. Effects of the angiotensin recep-
tor blocker azilsartan medoxomil versus olmesartan and valsartan on 
ambulatory and clinic blood pressure in patients with stages 1 and 
2 hypertension. Hypertension. 2011;57(3):413–420.
  26.  Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan 
medoxomil and olmesartan on ambulatory and clinic blood pressure.   
J Clin Hypertens (Greenwich). 2011;13(2):81–88.
  27.  Sica D, White WB, Weber MA, et al. Comparison of the novel 
angiotensin II receptor blocker azilsartan medoxomil vs valsartan by 
ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 
2011;13(7):467–472.
  28.  Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy 
and safety of azilsartan with that of candesartan cilexetil in Japanese 
patients with grade I–II essential hypertension: a randomized, double-
blind clinical study. Hypertens Res. 2012. [Epub ahead of print.]
  29.  Staessen JA, Thijs L, Li Y, et al. ‘Beyond blood pressure’ means mul-
tiple risk factor intervention, not pleiotropic antihypertensive drugs. 
Curr Opin Cardiol. 2007;22(4):335–343.
  30.  Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and 
independent effects of agents that inhibit the renin-angiotensin system. 
J Hypertens. 2007;25(5):951–958.
  31.  Nathan DM. Navigating the choices for diabetes prevention. N Engl J 
Med. 2010;362(16):1533–1535.
  32.  The NAVIGATOR Study Group. Effect of valsartan on the incidence 
of diabetes and cardiovascular events. N Engl J Med. 2010;362(16): 
1477–1490.
  33.  Bakris G. Are there effects of renin-angiotensin system antagonists   
beyond blood pressure control? Am J Cardiol. 2010;105(1 Suppl): 
21A–29A.
  34.  Bakris G, Burgess E, Weir M, Davidai G, Koval S, Investigators AS. 
Telmisartan is more effective than losartan in reducing proteinuria in 
patients with diabetic nephropathy. Kidney Int. 2008;74(3):364–369.
  35.  Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of 
diabetes incidence and weight loss in the Diabetes Prevention Program 
Outcomes Study. Lancet. 2009;374(9702):1677–1686.
  36.  Crandall JP, Knowler WC, Kahn SE, et al. The prevention of type 2 
diabetes. Nat Clin Pract Endocrinol Metab. 2008;4(7):382–393.
  37.  Tocci G, Paneni F, Palano F, et al. Angiotensin-converting enzyme 
inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of 
placebo-controlled clinical trials. Am J Hypertens. 2011;24(5):582–590.
  38.  Kohara Y, Imamiya E, Kubo K, Wada T, Inada Y, Naka T. A new class 
of angiotensin II receptor antagonists with a novel acidic bioisostere. 
Bioorganic Medicinal Chemistry Letters. 1995;5(17):1903–1908.
  39.  Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, Naka T. Synthesis 
and angiotensin II receptor antagonistic activities of benzimidazole 
derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. 
J Med Chem. 1996;39(26):5228–5235.
  40.  Naka T, Kubo K. A new class of diacidic nonpeptide angiotensin II   
receptor antagonists: candesartan cilexetil. Curr Pharm Des. 1999;5(6): 
 453–472.
  41.  Baker WL, White WB. Azilsartan medoxomil: a new angiotensin II 
receptor antagonist for treatment of hypertension. Ann Pharmacother. 
2011;45(12):1506–1515.
  42.  Ojima M, Igata H, Tanaka M, et al. In vitro antagonistic properties of a 
new angiotensin type 1 receptor blocker, azilsartan, in receptor binding 
and function studies. J Pharmacol Exp Ther. 2011;336(3):801–808.
  43.  Kusumoto K, Igata H, Ojima M, et al. Antihypertensive, insulin-
sensitising and renoprotective effects of a novel, potent and long-acting 
angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and 
dog models. Eur J Pharmacol. 2011;669(1–3):84–93.
  44.  McAdams MA, Governale LA, Swartz L, Hammad TA, Dal Pan GJ. 
Identifying patterns of adverse event reporting for four members of the 
angiotensin II receptor blockers class of drugs: revisiting the Weber 
effect. Pharmacoepidemiol Drug Saf. 2008;17(9):882–889.
  45.  Turnbull F, Neal B, Ninomiya T, et al. Effects of different regi-
mens to lower blood pressure on major cardiovascular events in 
older and younger adults: meta-analysis of randomised trials. BMJ. 
2008;336(7653):1121–1123.
  46.  Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive 
patients at high cardiovascular risk treated with regimens based 
on valsartan or amlodipine: the VALUE randomised trial. Lancet. 
2004;363(9426):2022–2031.
  47.  Kaplan NM. The choice of thiazide diuretics: why chlorthalidone may 
replace hydrochlorothiazide. Hypertension. 2009;54(5):951–953.
  48.  Messerli FH, Bangalore S. Half a century of hydrochlorothiazide: facts, 
fads, fiction, and follies. Am J Med. 2011;124(10):896–899.
  49.  Takeda Pharmaceuticals North America. Edarbyclor prescribing 
information. 2012. Available from: http://www.tpna.com/newsroom/
press_release_detail.aspx?year=2012&id=231. Accessed February 13, 
2012.
  50.  Zaiken K, Cheng JW. Azilsartan medoxomil: a new angiotensin receptor 
blocker. Clin Ther. 2011;33(11):1577–1589.
  51.  Center for Drug Evaluation and Research. Azilsartan medoxomil 
clinical pharmacology and biopharmaceutics review. New drug 
application to the Food and Drug Administration 2010; NDA 200796: 
1–26. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/
nda/2011/200796Orig1 s000ClinPharmR.pdf. Accessed July 14, 2011.
52.  Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new 
angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol. 
2001;41(5):515–527.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
142
Kurtz and KajiyaVascular Health and Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/vascular-health-and-risk-management-journal
Vascular Health and Risk Management is an international, peer-
reviewed journal of therapeutics and risk management, focusing on 
concise rapid reporting of clinical studies on the processes involved 
in the maintenance of vascular health; the monitoring, prevention and 
treatment of vascular disease and its sequelae; and the involvement of 
metabolic disorders, particularly diabetes. This journal is indexed on 
PubMed Central and MedLine. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Vascular Health and Risk Management 2012:8
  53.  Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: in 
vitro evidence for insurmountable antagonism and inverse agonism.   
Mol Cell Endocrinol. 2009;302(2):237–243.
  54.  Feghali RE, Nisse-Durgeat S, Asmar R. Effect of candesartan cilexetil 
on diabetic and non-diabetic hypertensive patients: meta-analysis of 
five randomized double-blind clinical trials. Vasc Health Risk Manag. 
2007;3(1):165–171.
  55.  Csajka C, Buclin T, Fattinger K, Brunner HR, Biollaz J. Population   
pharmacokinetic-pharmacodynamic modelling of angiotensin 
receptor blockade in healthy volunteers. Clin Pharmacokinet. 
2002;41(2):137–152.
  56.  Gleiter CH, Morike KE. Clinical pharmacokinetics of candesartan. Clin 
Pharmacokinet. 2002;41(1):7–17.
  57.  Kajiya T, Ho C, Wang J, Vilardi R, Kurtz TW. Molecular and cellular 
effects of azilsartan: a new generation angiotensin II receptor blocker. 
J Hypertens. 2011;29(12):2476–2483.
  58.  Vauquelin G, Van Liefde I. Slow antagonist dissociation and long-
lasting in vivo receptor protection. Trends Pharmacol Sci. 2006; 
27(7):356–359.
  59.  Iwai M, Chen R, Imura Y, Horiuchi M. TAK-536, a new AT1 receptor 
blocker, improves glucose intolerance and adipocyte differentiation. 
Am J Hypertens. 2007;20(5):579–586.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
143
Azilsartan versus other ARBs